在肝脏疾病诊断领域，FibroScan无创肝纤维化和脂肪肝变量化检测仪凭借其卓越的性能和广泛的临床验证，获得WHO 2024乙肝指南的权威推荐，成为肝纤维化无创诊断的金标准。这一国际背书不仅彰显了设备在全球肝病诊疗中的重要地位，更为医院管理者、采购 ...

在DRG/DIP支付改革与医疗质量评审双重要求下，医院管理者正面临肝病诊疗路径优化的关键命题——如何平衡诊断准确性、运营效率与成本控制？FibroScan®慢性肝病纤维化检测仪作为全球唯一同时获得WHO、FDA、欧洲肝脏研究学会(EASL)、美国肝病研究协会(AASLD ...

在肝病诊疗领域，肝纤维化瞬时弹性测定仪（以FibroScan®肝纤维化瞬时弹性测定仪为代表）已成为评估肝脏脂肪变性及纤维化的关键工具。然而，传统设备在临床应用中仍面临技术瓶颈：操作者手法差异导致结果波动、单次采样变异性高影响诊断可靠性、手动 ...

在医疗资源分布不均的大背景下，基层肝病防控一直是困扰医院管理者、采购部门及临床科室负责人的难题。以四川省凉山州为例， 2011-2020 年间该州累计报告丙肝病例超 2.2 万例，年均发病率持续位居四川省首位且呈波动上升趋势。设备短缺、专业人才不足等 ...

WALTHAM, Mass. & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Echosens North America, a high-technology company offering the FibroScan ® portfolio of solutions, and ChronWell, a digital health and ...

PHILADELPHIA — FibroScan screening for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis could significantly improve patient diagnosis and care, as data presented at the American ...

KUTV — Fatty liver disease is a chronic liver disease and is a rapidly growing problem here in Utah. It’s important to catch this disease early with a simple, non-invasive test and then make the ...

This milestone opens a path for FibroScan® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 ...

WALTHAM, Mass.--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan family of products, is pleased to announce that FibroScan has been added to the US Defense Logistics ...

The Tri-State’s TRUSTED news source. Click here to stay informed and subscribe to Herald-Dispatch. Click #isupportlocal for more information on supporting our local journalists. SCOTT DEPOT, W.Va. — ...

This milestone opens a path for FibroScan ® to ultimately replace liver biopsy for patient enrollment and treatment response assessment in MASH drug development WESTBOROUGH, Mass., Sept. 8, 2025 ...